FIXED COMBINATION OF THE CALCIUM CHANNEL BLOCKER LERCANIDIPINE AND ANGIOTENSIN CONVERTING ENZYME INHIBITOR ENALAPRIL: POSSIBILITY OF USAGE

Autor: I. I. Kopchenov, Olga D. Ostroumova
Jazyk: angličtina
Rok vydání: 2015
Předmět:
lcsh:Diseases of the circulatory (Cardiovascular) system
arterial hypertension
medicine.drug_class
chemistry.chemical_element
Calcium channel blocker
лерканидипин
RM1-950
Calcium
Pharmacology
антагонисты кальция
артериальная гипертония
combined therapy
calcium antagonists
medicine
Diseases of the circulatory (Cardiovascular) system
Pharmacology (medical)
Enalapril
комбинированная терапия
biology
fixed combinations of antihypertensive drugs
business.industry
Lercanidipine
lcsh:RM1-950
Antagonist
Dihydropyridine
Angiotensin-converting enzyme
lcsh:Therapeutics. Pharmacology
chemistry
ace inhibitors
lcsh:RC666-701
RC666-701
ACE inhibitor
biology.protein
эналаприл
Therapeutics. Pharmacology
фиксированные комбинации антигипертензивных препаратов
Cardiology and Cardiovascular Medicine
business
enalapril
lercanidipine
ингибиторы АПФ
medicine.drug
Zdroj: Racionalʹnaâ Farmakoterapiâ v Kardiologii, Vol 9, Iss 2, Pp 177-182 (2015)
ISSN: 2225-3653
1819-6446
Popis: Data on the updated approach to the choice of two-component antihypertensive combinations for different clinical situations are presented. Advantages and indications for combination of an angiotensin converting enzyme (ACE) inhibitor and dihydropyridine calcium antagonist are considered. Data on the efficacy and safety of the combination of calcium antagonist of the third generation, lercanidipine, and ACE inhibitor, enalapril, are presented.
Databáze: OpenAIRE
Externí odkaz: